CD95 pp 117-123 | Cite as

Boyden Chamber Assay to Study of Cell Migration Induced by Metalloprotease Cleaved-CD95L

Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1557)

Abstract

CD95 receptor, also called Fas or Apo-1, is a member of the tumor necrosis factor receptors (TNF-R) superfamily (Itoh and Nagata, J Biol Chem 268:10932–10937, 1993). Its cognate ligand, CD95L, is a transmembrane cytokine, which can be cleaved by metalloproteases (Matsuno et al., J Rheumatol 28:22–28, 2001; Vargo-Gogola et al., Arch Biochem Biophys 408:155–161, 2002; Kiaei et al., Exp Neurol 205:74–81, 2007; Schulte et al., Cell Death Differ 14:1040–1049, 2007) releasing a soluble ligand into the bloodstream. Recent work has shown that this metalloprotease-cleaved CD95L (cl-CD95L) is involved in carcinogenesis (Malleter et al., Cancer Res 73:6711–6721, 2013). Cl-CD95L also fuels the inflammatory process in patients affected by systemic lupus erythematosus by promoting the accumulation of activated T lymphocytes in enflamed organs (Tauzin et al., PLoS Biol 9:e1001090, 2011). This chapter aims at describing the methodology used to measure the chemoattractive effect of cl-CD95L on human cancer cells and lymphocytes.

Key words

Fas FasL Cell motility Cell migration Boyden chamber PI3K Metastasis 

References

  1. 1.
    Itoh N, Nagata S (1993) A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 268:10932–10937PubMedGoogle Scholar
  2. 2.
    Matsuno H et al (2001) Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound Fas ligand. J Rheumatol 28:22–28PubMedGoogle Scholar
  3. 3.
    Vargo-Gogola T et al (2002) Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys 408:155–161CrossRefPubMedGoogle Scholar
  4. 4.
    Kiaei M et al (2007) Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol 205:74–81. doi: 10.1016/j.expneurol.2007.01.036 CrossRefPubMedGoogle Scholar
  5. 5.
    Schulte M et al (2007) ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ 14:1040–1049. doi: 10.1038/sj.cdd.4402101 PubMedGoogle Scholar
  6. 6.
    Malleter M et al (2013) CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res 73:6711–6721CrossRefPubMedGoogle Scholar
  7. 7.
    Tauzin S et al (2011) The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. PLoS Biol 9:e1001090CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Schneider P et al (1998) Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 187:1205–1213CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Suda T et al (1997) Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 186:2045–2050CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Chen L et al (2010) CD95 promotes tumour growth. Nature 465:492–496. doi: 10.1038/nature09075 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kleber S et al (2008) Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13:235–248CrossRefPubMedGoogle Scholar
  12. 12.
    Boyden SV (1962) The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med 115:453–466CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.Centre Eugène MarquisRennesFrance
  2. 2.INSERM ERL440-OSSEquipe Labellisée Ligue Contre Le CancerRennesFrance
  3. 3.Université de Rennes-1RennesFrance

Personalised recommendations